Female genital cancer evaluation method
Female genital cancer evaluation method
 CN 102,057,276 A
 Filed: 06/22/2009
 Published: 05/11/2011
 Est. Priority Date: 06/20/2008
 Status: Active Application
First Claim
1. the evaluation method of female sex organs cancer is characterized in that, this method comprises the steps:
 Determination step is at the blood measuring that collects from the evaluation object amino acid concentration data relevant with the amino acid concentration value;
Concentration value benchmark evaluation step, at least a amino acid whose abovementioned concentration value in the abovementioned amino acid concentration data according to the abovementioned evaluation object of in the said determination step, measuring among contained Thr, Ser, Asn, Gln, Pro, Gly, Ala, Cit, Val, Met, Ile, Leu, Tyr, Phe, His, Trp, Orn, Lys, the Arg, for abovementioned evaluation object, estimate the state of the female sex organs cancer that comprises at least a cancer in cervical carcinoma, carcinoma of uterine body and the oophoroma.
Chinese PRB Reexamination
Abstract
Disclosed is a female genital cancer evaluation method which can evaluate the condition of female genital cancer with high accuracy by utilizing, among the blood concentrations of amino acids, the blood concentration of an amino acid involved in the condition of the female genital cancer. The female genital cancer evaluation method comprises the steps of: measuring an amino acid concentration data associated with the concentrations of amino acids in the blood collected from a subject to be evaluated; and evaluating the condition of female genital cancer including at least one member selected from uterine cervical cancer, uterine body cancer and ovarian cancer in the subject based on the value of the concentration of at least one member selected from Thr, Ser, Asn, Gln, Pro, Gly, Ala, Cit, Val, Met, Ile, Leu, Tyr, Phe, His, Trp, Orn, Lys and Arg included in the amino acid concentration data for the subject measured in the aforementioned step.

3 Citations
No References
Apparatus and method for processing information concerning biological condition, system, program and recording medium for managing information concerning biological condition  
Patent #
CN 1,744,850 A
Filed 12/09/2003

Current Assignee

BIOCONDITION EVALUATING DEVICE, BIOCONDITION EVALUATING METHOD, BIOCONDITION EVALUATING SYSTEM, BIOCONDITION EVALUATING PROGRAM, EVALUATION FUNCTION GENERATING DEVICE, EVALUATION FUNCTION GENERATING METHOD, EVALUATION FUNCTION GENERATING PROGRAM, AND RECORDING MEDIUM  
Patent #
EP1862797A1
Filed 03/07/2006

Current Assignee

METHOD FOR EVALUATION OF LUNG CANCER, LUNG CANCER EVALUATION APPARATUS, LUNG CANCER EVALUATION METHOD, LUNG CANCER EVALUATION SYSTEM, LUNG CANCER EVALUATION PROGRAM, AND RECORDING MEDIUM  
Patent #
WO2008016111A1
Filed 08/02/2007

Current Assignee

19 Claims

1. the evaluation method of female sex organs cancer is characterized in that, this method comprises the steps:

Determination step is at the blood measuring that collects from the evaluation object amino acid concentration data relevant with the amino acid concentration value; Concentration value benchmark evaluation step, at least a amino acid whose abovementioned concentration value in the abovementioned amino acid concentration data according to the abovementioned evaluation object of in the said determination step, measuring among contained Thr, Ser, Asn, Gln, Pro, Gly, Ala, Cit, Val, Met, Ile, Leu, Tyr, Phe, His, Trp, Orn, Lys, the Arg, for abovementioned evaluation object, estimate the state of the female sex organs cancer that comprises at least a cancer in cervical carcinoma, carcinoma of uterine body and the oophoroma.


2. the evaluation method of the described female sex organs cancer of claim 1, it is characterized in that, abovementioned concentration value benchmark evaluation step further comprises following concentration value benchmark discriminating step:
 according to contained Thr in the abovementioned amino acid concentration data of the abovementioned evaluation object of measuring in the said determination step, Ser, Asn, Gln, Pro, Gly, Ala, Cit, Val, Met, Ile, Leu, Tyr, Phe, His, Trp, Orn, Lys, at least a amino acid whose abovementioned concentration value among the Arg, for abovementioned evaluation object, differentiation is that abovementioned female sex organs cancer also is nonfemale sex organs cancer;
Be a kind of cancer or the abovementioned nonfemale sex organs cancer in abovementioned cervical carcinoma, abovementioned carcinoma of uterine body, the abovementioned oophoroma;
Be that a kind of cancer in abovementioned cervical carcinoma, the abovementioned carcinoma of uterine body also is a kind of cancer in noncervical carcinoma, the noncarcinoma of uterine body;
Be abovementioned cervical carcinoma or abovementioned noncervical carcinoma;
Be abovementioned carcinoma of uterine body or abovementioned noncarcinoma of uterine body;
Be that abovementioned oophoroma also is nonoophoroma;
Be that the female sex organs cancer is suffered from risk group or healthy group;
It perhaps whether is any cancer in abovementioned cervical carcinoma, abovementioned carcinoma of uterine body, the abovementioned oophoroma.
 according to contained Thr in the abovementioned amino acid concentration data of the abovementioned evaluation object of measuring in the said determination step, Ser, Asn, Gln, Pro, Gly, Ala, Cit, Val, Met, Ile, Leu, Tyr, Phe, His, Trp, Orn, Lys, at least a amino acid whose abovementioned concentration value among the Arg, for abovementioned evaluation object, differentiation is that abovementioned female sex organs cancer also is nonfemale sex organs cancer;

3. the evaluation method of the described female sex organs cancer of claim 1 is characterized in that, abovementioned concentration value benchmark evaluation step further comprises the steps:

The discriminant value calculation procedure, at least a amino acid whose abovementioned concentration value in the abovementioned amino acid concentration data according to the abovementioned evaluation object of in the said determination step, measuring among contained Thr, Ser, Asn, Gln, Pro, Gly, Ala, Cit, Val, Met, Ile, Leu, Tyr, Phe, His, Trp, Orn, Lys, the Arg and be the predefined multivariate discriminant of parameter with abovementioned amino acid concentration, the value of calculating this multivariate discriminant is a discriminant value; Discriminant value benchmark evaluation step according to the abovementioned discriminant value of calculating, is estimated the state of abovementioned female sex organs cancer for abovementioned evaluation object in abovementioned discriminant value calculation procedure, Abovementioned multivariate discriminant is contained at least a amino acid among Thr, Ser, Asn, Gln, Pro, Gly, Ala, Cit, Val, Met, Ile, Leu, Tyr, Phe, His, Trp, Orn, Lys, the Arg as abovementioned parameter.


4. the evaluation method of the described female sex organs cancer of claim 3, it is characterized in that, abovementioned discriminant value benchmark evaluation step further comprises following discriminant value benchmark discriminating step:
 according to the abovementioned discriminant value of calculating in abovementioned discriminant value calculation procedure, for abovementioned evaluation object, differentiation is that abovementioned female sex organs cancer also is nonfemale sex organs cancer;
Be a kind of cancer or the abovementioned nonfemale sex organs cancer in abovementioned cervical carcinoma, abovementioned carcinoma of uterine body, the abovementioned oophoroma;
Be that a kind of cancer in abovementioned cervical carcinoma, the abovementioned carcinoma of uterine body also is a kind of cancer in noncervical carcinoma, the noncarcinoma of uterine body;
Be abovementioned cervical carcinoma or abovementioned noncervical carcinoma;
Be abovementioned carcinoma of uterine body or abovementioned noncarcinoma of uterine body;
Be that abovementioned oophoroma also is nonoophoroma;
Be that the female sex organs cancer is suffered from risk group or healthy group;
It perhaps whether is any cancer in abovementioned cervical carcinoma, abovementioned carcinoma of uterine body, the abovementioned oophoroma.
 according to the abovementioned discriminant value of calculating in abovementioned discriminant value calculation procedure, for abovementioned evaluation object, differentiation is that abovementioned female sex organs cancer also is nonfemale sex organs cancer;

5. the evaluation method of the described female sex organs cancer of claim 4, it is characterized in that abovementioned multivariate discriminant is:
 1 fractional expression or a plurality of abovementioned fractional expression sum or logistic regression formula, linear discriminent, multiple regression formula, the formula of making by support vector machine, the formula of making according to the mahalanobis distance method, the formula of making by typical discriminatory analysis, by the arbitrary formula in the formula of decision tree making.

6. the evaluation method of the described female sex organs cancer of claim 5 is characterized in that:

Abovementioned discriminant value calculation procedure is according to contained Thr in the abovementioned amino acid concentration data of the abovementioned evaluation object of measuring in the said determination step, Ser, Asn, Gln, Pro, Ala, Val, Met, Ile, Leu, Tyr, Phe, His, Trp, Orn, at least a amino acid whose abovementioned concentration value among the Arg and contain Thr, Ser, Asn, Gln, Pro, Ala, Val, Met, Ile, Leu, Tyr, Phe, His, Trp, Orn, at least a amino acid among the Arg calculates abovementioned discriminant value as the abovementioned multivariate discriminant of abovementioned parameter Abovementioned discriminant value benchmark discriminating step is according to the abovementioned discriminant value of calculating in abovementioned discriminant value calculation procedure, for abovementioned evaluation object, differentiation is a kind of cancer or the abovementioned nonfemale sex organs cancer in abovementioned cervical carcinoma, abovementioned carcinoma of uterine body, the abovementioned oophoroma.


7. the evaluation method of the described female sex organs cancer of claim 6, it is characterized in that abovementioned multivariate discriminant is:
 with Gln, His, Arg as the abovementioned fractional expression of abovementioned parameter, with aABA, His, Met as the abovementioned fractional expression of abovementioned parameter, with Ile, His, Cit, Arg, Tyr, Trp as the abovementioned fractional expression of abovementioned parameter or with aABA, Cit, Met abovementioned fractional expression as abovementioned parameter;
With Gly, Val, His, Arg as the abovementioned linear discriminent of abovementioned parameter, with Gly, aABA, Met, His as the abovementioned linear discriminent of abovementioned parameter, with Ala, Ile, His, Trp, Arg as the abovementioned linear discriminent of abovementioned parameter, with Gly, Cit, Met, Phe as the abovementioned linear discriminent of abovementioned parameter or with His, Leu, Met, Cit, Ile, Tyr abovementioned linear discriminent as abovementioned parameter;
Or with Val, Leu, His, Arg as the abovementioned logistic regression formula of abovementioned parameter, with aABA, Met, Tyr, His as the abovementioned logistic regression formula of abovementioned parameter, with Val, Ile, His, Trp, Arg as the abovementioned logistic regression formula of abovementioned parameter, with Cit, aABA, Met, Tyr as the abovementioned logistic regression formula of abovementioned parameter or with His, Leu, Met, Cit, Ile, Tyr abovementioned logistic regression formula as abovementioned parameter.
 with Gln, His, Arg as the abovementioned fractional expression of abovementioned parameter, with aABA, His, Met as the abovementioned fractional expression of abovementioned parameter, with Ile, His, Cit, Arg, Tyr, Trp as the abovementioned fractional expression of abovementioned parameter or with aABA, Cit, Met abovementioned fractional expression as abovementioned parameter;

8. the evaluation method of the described female sex organs cancer of claim 5 is characterized in that:

Abovementioned discriminant value calculation procedure is according to contained Thr in the abovementioned amino acid concentration data of the abovementioned evaluation object of measuring in the said determination step, Ser, Asn, Pro, Gly, Cit, Val, Met, Ile, Leu, Phe, His, Trp, Orn, Lys, at least a amino acid whose abovementioned concentration value among the Arg and contain Thr, Ser, Asn, Pro, Gly, Cit, Val, Met, Ile, Leu, Phe, His, Trp, Orn, Lys, at least a amino acid among the Arg calculates abovementioned discriminant value as the abovementioned multivariate discriminant of abovementioned parameter Abovementioned discriminant value benchmark discriminating step is according to the abovementioned discriminant value of calculating in abovementioned discriminant value calculation procedure, for abovementioned evaluation object, differentiation is a kind of cancer in a kind of cancer in abovementioned cervical carcinoma, the abovementioned carcinoma of uterine body or abovementioned noncervical carcinoma, the abovementioned noncarcinoma of uterine body.


9. the evaluation method of the described female sex organs cancer of claim 8, it is characterized in that abovementioned multivariate discriminant is:
 with Lys, His, Arg as the abovementioned fractional expression of abovementioned parameter, with aABA, His, Met as the abovementioned fractional expression of abovementioned parameter or with Ile, His, Cit, Arg abovementioned fractional expression as abovementioned parameter;
With Gly, Val, His, Arg as the abovementioned linear discriminent of abovementioned parameter, with Gly, Phe, His, Arg as the abovementioned linear discriminent of abovementioned parameter, with Cit, Ile, His, Arg as the abovementioned linear discriminent of abovementioned parameter or with His, Leu, Met, Cit, Ile, Tyr abovementioned linear discriminent as abovementioned parameter;
Or with Val, His, Lys, Arg as the abovementioned logistic regression formula of abovementioned parameter, with Thr, aABA, Met, His as the abovementioned logistic regression formula of abovementioned parameter, with Cit, Ile, His, Arg as the abovementioned logistic regression formula of abovementioned parameter or with His, Leu, Met, Cit, Ile, Tyr abovementioned logistic regression formula as abovementioned parameter.
 with Lys, His, Arg as the abovementioned fractional expression of abovementioned parameter, with aABA, His, Met as the abovementioned fractional expression of abovementioned parameter or with Ile, His, Cit, Arg abovementioned fractional expression as abovementioned parameter;

10. the evaluation method of the described female sex organs cancer of claim 5 is characterized in that:

Abovementioned discriminant value calculation procedure is that at least a amino acid whose abovementioned concentration value among Asn, Val contained in the abovementioned amino acid concentration data according to the abovementioned evaluation object measured in the said determination step, Met, Leu, Phe, His, Trp, Orn, Lys, the Arg and at least a amino acid that contains among Asn, Val, Met, Leu, Phe, His, Trp, Orn, Lys, the Arg calculate abovementioned discriminant value as the abovementioned multivariate discriminant of abovementioned parameter Abovementioned discriminant value benchmark discriminating step is that for abovementioned evaluation object, differentiation is abovementioned cervical carcinoma or abovementioned noncervical carcinoma according to the abovementioned discriminant value of calculating in abovementioned discriminant value calculation procedure.


11. the evaluation method of the described female sex organs cancer of claim 10, it is characterized in that abovementioned multivariate discriminant is:
 with aABA, His, Val as the abovementioned fractional expression of abovementioned parameter, with aABA, Met, Val as the abovementioned fractional expression of abovementioned parameter or with Met, His, Cit, Arg abovementioned fractional expression as abovementioned parameter;
With Gly, Val, His, Arg as the abovementioned linear discriminent of abovementioned parameter, with Gly, Val, Met, Lys as the abovementioned linear discriminent of abovementioned parameter, with Cit, Met, His, Arg as the abovementioned linear discriminent of abovementioned parameter or with His, Leu, Met, Ile, Tyr, Lys abovementioned linear discriminent as abovementioned parameter;
Or with Val, Leu, His, Arg as the abovementioned logistic regression formula of abovementioned parameter, with Met, His, Orn, Arg as the abovementioned logistic regression formula of abovementioned parameter, with Val, Tyr, His, Arg as the abovementioned logistic regression formula of abovementioned parameter or with His, Leu, Met, Ile, Tyr, Lys abovementioned logistic regression formula as abovementioned parameter.
 with aABA, His, Val as the abovementioned fractional expression of abovementioned parameter, with aABA, Met, Val as the abovementioned fractional expression of abovementioned parameter or with Met, His, Cit, Arg abovementioned fractional expression as abovementioned parameter;

12. the evaluation method of the described female sex organs cancer of claim 5 is characterized in that:

Abovementioned discriminant value calculation procedure is according to contained Thr in the abovementioned amino acid concentration data of the abovementioned evaluation object of measuring in the said determination step, Ser, Asn, Pro, Gly, Cit, Val, Met, Ile, Leu, Phe, His, Trp, at least a amino acid whose abovementioned concentration value among the Arg and contain Thr, Ser, Asn, Pro, Gly, Cit, Val, Met, Ile, Leu, Phe, His, Trp, at least a amino acid among the Arg calculates abovementioned discriminant value as the abovementioned multivariate discriminant of abovementioned parameter Abovementioned discriminant value benchmark discriminating step is that for abovementioned evaluation object, differentiation is abovementioned carcinoma of uterine body or abovementioned noncarcinoma of uterine body according to the abovementioned discriminant value of calculating in abovementioned discriminant value calculation procedure.


13. the evaluation method of the described female sex organs cancer of claim 12, it is characterized in that abovementioned multivariate discriminant is:
 with Lys, His, Arg as the abovementioned fractional expression of abovementioned parameter, with aABA, His, Met as the abovementioned fractional expression of abovementioned parameter or with Ile, His, Asn, Cit abovementioned fractional expression as abovementioned parameter;
With Gln, His, Lys, Arg as the abovementioned linear discriminent of abovementioned parameter, with Gly, Met, Phe, His as the abovementioned linear discriminent of abovementioned parameter, with Cit, Ile, His, Arg as the abovementioned linear discriminent of abovementioned parameter or with His, Asn, Val, Pro, Cit, Ile abovementioned linear discriminent as abovementioned parameter;
Or with Gln, Gly, His, Arg as the abovementioned logistic regression formula of abovementioned parameter, with Gln, Phe, His, Arg as the abovementioned logistic regression formula of abovementioned parameter, with Gln, Ile, His, Arg as the abovementioned logistic regression formula of abovementioned parameter or with His, Asn, Val, Pro, Cit, Ile abovementioned logistic regression formula as abovementioned parameter.
 with Lys, His, Arg as the abovementioned fractional expression of abovementioned parameter, with aABA, His, Met as the abovementioned fractional expression of abovementioned parameter or with Ile, His, Asn, Cit abovementioned fractional expression as abovementioned parameter;

14. the evaluation method of the described female sex organs cancer of claim 5 is characterized in that:

Abovementioned discriminant value calculation procedure is according to contained Thr in the abovementioned amino acid concentration data of the abovementioned evaluation object of measuring in the said determination step, Ser, Asn, Gln, Ala, Cit, Val, Met, Ile, Leu, Tyr, Phe, His, Trp, Orn, Lys, at least a amino acid whose abovementioned concentration value among the Arg and contain Thr, Ser, Asn, Gln, Ala, Cit, Val, Met, Ile, Leu, Tyr, Phe, His, Trp, Orn, Lys, at least a amino acid among the Arg calculates abovementioned discriminant value as the abovementioned multivariate discriminant of abovementioned parameter Abovementioned discriminant value benchmark discriminating step is that for abovementioned evaluation object, differentiation is abovementioned oophoroma or abovementioned nonoophoroma according to the abovementioned discriminant value of calculating in abovementioned discriminant value calculation procedure.


15. the evaluation method of the described female sex organs cancer of claim 14, it is characterized in that abovementioned multivariate discriminant is:
 with Orn, Cit, Met as the abovementioned fractional expression of abovementioned parameter, with Gln, Cit, Tyr as the abovementioned fractional expression of abovementioned parameter or with Orn, His, Phe, Trp abovementioned fractional expression as abovementioned parameter;
With Ser, Cit, Orn, Trp as the abovementioned linear discriminent of abovementioned parameter, with Ser, Cit, Ile, Orn as the abovementioned linear discriminent of abovementioned parameter, with Phe, Trp, Orn, Lys as the abovementioned linear discriminent of abovementioned parameter or with His, Trp, Glu, Cit, Ile, Orn abovementioned linear discriminent as abovementioned parameter;
Or with Ser, Cit, Trp, Orn as the abovementioned logistic regression formula of abovementioned parameter, with Gln, Cit, Ile, Tyr as the abovementioned logistic regression formula of abovementioned parameter, with Asn, Phe, His, Trp as the abovementioned logistic regression formula of abovementioned parameter or with His, Trp, Glu, Cit, Ile, Orn abovementioned logistic regression formula as abovementioned parameter.
 with Orn, Cit, Met as the abovementioned fractional expression of abovementioned parameter, with Gln, Cit, Tyr as the abovementioned fractional expression of abovementioned parameter or with Orn, His, Phe, Trp abovementioned fractional expression as abovementioned parameter;

16. the evaluation method of the described female sex organs cancer of claim 5 is characterized in that:

Abovementioned discriminant value calculation procedure is according to contained Thr in the abovementioned amino acid concentration data of the abovementioned evaluation object of measuring in the said determination step, Ser, Asn, Gln, Pro, Ala, Val, Met, Ile, Leu, Tyr, Phe, His, Trp, Orn, at least a amino acid whose abovementioned concentration value among the Arg and contain Thr, Ser, Asn, Gln, Pro, Ala, Val, Met, Ile, Leu, Tyr, Phe, His, Trp, Orn, at least a amino acid among the Arg calculates abovementioned discriminant value as the abovementioned multivariate discriminant of abovementioned parameter Abovementioned discriminant value benchmark discriminating step is according to the abovementioned discriminant value of calculating in abovementioned discriminant value calculation procedure, and for abovementioned evaluation object, differentiation is that abovementioned female sex organs cancer is suffered from risk group or abovementioned healthy group.


17. the evaluation method of the described female sex organs cancer of claim 16, it is characterized in that abovementioned multivariate discriminant is:
 with Phe, His, Met, Pro, Lys, Arg as the abovementioned linear discriminent of abovementioned parameter or with Phe, His, Met, Pro, Lys, Arg abovementioned logistic regression formula as abovementioned parameter.

18. the evaluation method of the described female sex organs cancer of claim 5 is characterized in that:

Abovementioned discriminant value calculation procedure is according to contained Thr in the abovementioned amino acid concentration data of the abovementioned evaluation object of measuring in the said determination step, Ser, Asn, Glu, Gln, Pro, Gly, Ala, Cit, ABA, Val, Met, Ile, Leu, Tyr, Phe, His, Trp, Orn, Lys, at least a amino acid whose abovementioned concentration value among the Arg and contain Thr, Ser, Asn, Glu, Gln, Pro, Gly, Ala, Cit, ABA, Val, Met, Ile, Leu, Tyr, Phe, His, Trp, Orn, Lys, at least a amino acid among the Arg calculates abovementioned discriminant value as the abovementioned multivariate discriminant of abovementioned parameter Abovementioned discriminant value benchmark discriminating step is according to the abovementioned discriminant value of calculating in abovementioned discriminant value calculation procedure, and whether for abovementioned evaluation object, differentiating is any cancer in abovementioned cervical carcinoma, abovementioned carcinoma of uterine body, the abovementioned oophoroma.


19. the evaluation method of the described female sex organs cancer of claim 18, it is characterized in that abovementioned multivariate discriminant is:
 with Cit, Met, Lys, Asn, Ala, Thr, Gln, aABA as the formula of making according to abovementioned mahalanobis distance method of abovementioned parameter or with His, Leu, Ser, Thr, Glu, Gln, Ala, Lys the formula of making according to abovementioned mahalanobis distance method as abovementioned parameter.
Specification(s)